Phase 1/2 ONCT-534 Study: Patient Enrollment in Third Dosing Cohort for mCRPC

Oncternal Therapeutics is a biopharmaceutical firm that is dedicated to the development of innovative treatments for patients suffering from cancers with significant unmet medical needs. The company's strategy is centered on targeting biological pathways that are implicated in the development and progression of cancer, which are currently underexplored. They are particularly focused on hematological malignancies and prostate cancer, with a diverse pipeline of treatments under development.
The company is currently enrolling patients for two clinical trials. The first is a Phase 1/2 study for ONCT-808, an autologous cell therapy that targets ROR1, which is being studied for its potential to treat patients with relapsed or refractory B-cell malignancies. The second trial is a Phase 1/2 study for ONCT-534, a dual-action androgen receptor inhibitor, which is being investigated for its efficacy in treating patients with metastatic castration-resistant prostate cancer who have relapsed or are refractory to approved androgen receptor pathway inhibitors.
ONCT-534 is an experimental drug that has shown preclinical activity against prostate cancer, including against various forms of androgen receptor aberrations. The drug is designed to address the unmet medical needs of patients with advanced metastatic prostate cancer, particularly those with resistance to current treatments. The ongoing study, ONCT-534-101, is a Phase 1/2 trial aimed at evaluating the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of ONCT-534 in patients with mCRPC.
Additionally, Oncternal is developing ONCT-808, a CAR T cell therapy that targets the ROR1 receptor using the binding domain from zilovertamab. This therapy has shown activity against multiple types of cancers and is specific to cancer cells expressing ROR1. The company has also developed a manufacturing process that could reduce the waiting time for patients to receive their personalized CAR T therapy.
Zilovertamab, another drug in Oncternal's portfolio, is a monoclonal antibody designed to inhibit ROR1 function. It has been evaluated in combination with ibrutinib for the treatment of various types of leukemia and lymphoma, showing promising results in patients with specific genetic markers.
The company's commitment to advancing novel oncology therapies is evident in their ongoing clinical trials and the development of new drugs that target specific cancer pathways. Their work holds the potential to significantly improve the treatment options available to patients with certain types of cancer, offering hope for those who have exhausted other therapeutic options.